In vivo long-term kinetics of radiolabeled N,N-dimethyltryptamine and tryptamine

Journal of Nuclear Medicine

Volumn 52, Issue 6, 2011, Pages 970-977

  Vitale, Arturo A ^a   Pomilio, Alicia B ^a   Cañellas, Carlos O ^b   Vitale, Martín G ^a   Putz, Eva Maria ^a,c   Ciprian Ollivier, Jorge ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Tecnonuclear SA   (Argentina)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

131I N,N dimethyltryptamine; 131I tryptamine; Planar imaging studies

Indexed keywords

2 IODO N,N DIMETHYLTRYPTAMINE; 2 IODO TRYPTAMINE; 3 INDOLEMETHANOL; IODINE 131; N,N DIMETHYLTRYPTAMINE; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN TRANSPORTER; TRYPTAMINE; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIORAL SCIENCE; BLOOD BRAIN BARRIER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG DEGRADATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG UPTAKE; HALLUCINATION; IMAGE ANALYSIS; IN VIVO STUDY; ISOTOPE LABELING; MALE; MEAN RESIDENCE TIME; NONHUMAN; OLFACTORY BULB; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN SECRETION; RABBIT; RADIOIODINATION; URINARY EXCRETION;

ANIMALS; BRAIN; ISOTOPE LABELING; KIDNEY; LIPIDS; MAGNETIC RESONANCE SPECTROSCOPY; N,N-DIMETHYLTRYPTAMINE; OLFACTORY BULB; POSITRON-EMISSION TOMOGRAPHY; RABBITS; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; RECEPTORS, SEROTONIN; SOLUBILITY; TISSUE DISTRIBUTION; TRYPTAMINES;

EID: 79958099202     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.083246     Document Type: Article

References (37)

1. Pomilio AB, Vitale AA, Ciprian Ollivier J, Cetkovich Bakmas M, Gómez R, Vázquez G. Ayahoasca: an experimental psychosis that mirrors the transmethylation hypothesis of schizophrenia. J Ethnopharmacol. 1999;65:29-51. (Pubitemid 29193062)
2. Pomilio AB, Vitale A, Ciprian Ollivier J, Cetkovich Bakmas MA. Chemical approach to the understanding of schizophrenia. An Asoc Quim Argent. 1998;86:320-335.
3. Pomilio AB, Vitale A, Ciprian Ollivier J. Cult-Hoasca: a model for schizophrenia. Mol Med Chem. 2003;1:1-7.
4. Buchanan MS, Carroll AR, Pass D, Quinn RJ. NMR spectral assignments of a new chlorotryptamine alkaloid and its analogues from Acacia confusa. Magn Reson Chem. 2007;45:359-361.
5. Tempone AG, Sartorelli P, Teixeira D, et al. Brazilian flora extracts as source of novel antileishmanial and antifungal compounds. Mem Inst Oswaldo Cruz. 2008;103:443-449.
6. Jacob MS, Presti DE. Endogenous psychoactive tryptamines reconsidered: an anxiolytic role for dimethyltryptamine. Med Hypotheses. 2005;64:930-937. (Pubitemid 40385946)
7. Barker SA, Monti JA, Christian ST. N,N-dimethyltryptamine: an endogenous hallucinogen. Int Rev Neurobiol. 1981;22:83-110.
8. Checkley SA, Murray RM, Oon MC, Rodnight R, Birley JL. A longitudinal study of urinary excretion of N,N-dimethyltryptamine in psychotic patients. Br J Psychiatry. 1980;137:236-239. (Pubitemid 10048857)
9. Ciprian-Ollivier J, Cetkovich-Bakmas MG. Altered consciousness states and endogenous psychoses: a common molecular pathway? Schizophr Res. 1997;28:257-265.
10. Phillips ML. Understanding the neurobiology of emotion perception: implications for psychiatry. Br J Psychiatry. 2003;182:190-192. (Pubitemid 36286728)
11. 2C receptors. Pharmacol Biochem Behav. 1998;61:323-330.
12. Fontanilla D, Johannessen M, Hajipour AR, Cozzi NV, Jackson MB, Ruoho AE. The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous s-1 receptor regulator. Science. 2009;323:934-937.
13. Su T-P, Hayashi T, Vaupel DB. When the endogenous hallucinogenic trace amine N,N-dimethyltryptamine meets the s-1 receptor. Sci Signal. 2009;2:pe12.
14. Attanasio A, Rager K, Gupta D. Ontogeny of circadian rhythmicity for melatonin, serotonin, and N-acetylserotonin. J Pineal Res. 1986;3:251-256. (Pubitemid 17192684)
15. 125I] iodomelatonin labels multiple binding sites in hamster brain. Biochem Biophys Res Commun. 1987;147:949-956.
16. Cohen H, Mertens J, Maziere B. Radioiodination reaction for radiopharmaceuticals. Compendium of effective strategies synthesis. Dordrecht, The Netherlands: Springer; 2006.
17. 131I derivatives of indolealkylamines for brain mapping. J Labelled Comp Radiopharm. 1997;39:677-684.
18. Strassman R. DMT: The Spirit Molecule: A Doctor's Revolutionary Research into the Biology of Near-Death and Mystical Experiences. Rochester, VT: Park Street Press, a Division of Inner Traditions International; 2001.
19. McEwen CM Jr., Sober AJ. Rabbit serum monoamine oxidase. II. Determinants of substrate specificity. J Biol Chem. 1967;242:3068-3078.
20. Stahl SM. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 3rd ed. Cambridge, NY: Cambridge University Press; 2008.
21. Kalat JW. Biological Psychology. 10th ed. Belmont, CA: Wadsworth Pub Co.; 2009.
22. Ffytche DH. The hodology of hallucinations. Cortex. 2008;44:1067-1083.
23. O'Connor S, Jacob TJC. Neuropharmacology of the olfactory bulb. Curr Mol Pharmacol. 2008;1:181-190.
24. Dahlström A, Fuxe K. Evidence for the existence of monoamine neurons in the central nervous system. II. Experimentally induced changes in the intraneuronal amine levels of bulbospinal neurons systems. Acta Physiol Scand Suppl. 1965;(suppl 247):1-36.
25. Descarries L, Riad M, Parent M. Ultrastructure of the serotonin innervation in the mammalian central nervous system. In: Müller CP, Jacobs BL, eds. Handbook of Behavioral Neuroscience. Burlington, VT: Elsevier BV, Academic Press; 2010:65-101.
26. Krautwurst D. Human olfactory receptor families and their odorants. Chem Biodivers. 2008;5:842-852.
27. McLean JH, Harley CW, Darby-King A, Yuan Q. pCREB in the neonate rat olfactory bulb is selectively and transiently increased by odor preference-conditioned training. Learn Mem. 1999;6:608-618. (Pubitemid 30033388)
28. 1A mediated autoregulation predicts amygdala reactivity. Nat Neurosci. 2006;9:1362-1363.
29. Jenner P, Marsden CD, Thanki CM. Behavioural changes induced by N,N-dimethyltryptamine in rodents. Br J Pharmacol. 1980;69:69-80. (Pubitemid 10101678)
30. 2 receptors. Biochem Pharmacol. 1991;41:1739-1744.
31. Borowsky B, Adham N, Jones KA, et al. Trace amines: identification of a family of mammalian G protein-coupled receptors. Proc Natl Acad Sci USA. 2001;98:8966-8971. (Pubitemid 32743853)
32. Ray LB. Biogenic amine receptors. Sci Signal. 2009;2:ec231.
33. Bunzow JR, Sonders MS, Arttamangkul S, et al. Amphetamine, 3,4-methylene-dioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol. 2001;60:1181-1188.
34. Aydar E, Palmer CP, Klyachko VA, Jackson MB. The s receptor as a ligand-regulated auxiliary potassium channel subunit. Neuron. 2002;34:399-410. (Pubitemid 34465498)
35. Johannessen M, Ramachandran S, Riemer L, Ramos-Serrano A, Ruoho AE, Jackson MB. Voltage-gated sodium channel modulation by sigma-receptors in cardiac myocytes and heterologous systems. Am J Physiol Cell Physiol. 2009;296:C1049-C1057.
36. Nagai F, Nonaka R, Kamimura KSH. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol. 2007;559:132-137. (Pubitemid 46295399)
37. Cozzi NV, Gopalakrishnan A, Anderson LL, et al. Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter. J Neural Transm. 2009;116:1591-1599.